Skip to main
CERT
CERT logo

Certara (CERT) Stock Forecast & Price Target

Certara (CERT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Certara Inc. is dedicated to enhancing the speed and efficiency of drug development through its innovative biosimulation software and technology, which are critical in optimizing the process of bringing medicines to market. The company's strategic focus on improving modeling and simulation capabilities has positioned it favorably within the biopharmaceutical sector, evidenced by growth driven by heightened demand for regulatory science services. Furthermore, the presence in key revenue-generating markets, including the Americas, EMEA, and Asia Pacific, supports a robust growth trajectory that reflects an increasing global need for effective drug discovery solutions.

Bears say

Certara Inc faces challenges with its production efficiency, as indicated by a slight decline in output associated with lower-grade stockpiles at its CIL plant. Furthermore, the company's valuation of the Mont Sorcier Project appears overly conservative at $22.0 million, especially in light of its 2022 financial summary that showed a significantly higher net present value of $1.6 billion based on prior metals pricing. The potential benefits stemming from changes in corporate income tax rates under Milei’s Regime for Large Investments may not be sufficient to offset these operational and valuation issues, contributing to a negative outlook for the company's stock.

Certara (CERT) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Certara and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Certara (CERT) Forecast

Analysts have given Certara (CERT) a Buy based on their latest research and market trends.

According to 7 analysts, Certara (CERT) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Certara (CERT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.